LINC02363: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02363

NCBI ID: G728175

LINC02363

Other Name(s): long intergenic non-protein coding RNA 2363 | Long intergenic non-protein coding RNA 2363

LINC02363: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02363 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure, length, and location, which makes it an interesting candidate for drug targeting and biomarker development. In this article, we will explore the potential of LINC02363 as a drug target and biomarker.

Structure and Function

The LINC02363 RNA

LINC02363 is a 21.9 kilobase (kb) RNA molecule that is located between exons 21 and 22 of the X chromosome in humans. It has a unique 5' end that is specific to the X chromosome, and a 3' end that is located at position -129.2 on the X chromosome. The LINC02363 RNA is composed of 11 exons that are predominantly intron-containing, with the exception of exon 21 (1.1 kb), which is exonic.

The LINC02363 RNA is characterized by its unique structure, which consists of a alternating sequence of non-coding regions (ncRNAs) and coding regions (cDNA). The LINC02363 RNA has a characteristic stem-loop structure that is composed of three' enders and a unique 5' end that is specific to the X chromosome. The LINC02363 RNA also has a higher-than-normal number of exons, which suggests that it may be involved in the regulation of gene expression.

Expression and Function

LINC02363 RNA Expression

Several studies have demonstrated that the LINC02363 RNA is expressed in various tissues and cells, including brain, heart, liver, and muscle. Expression analysis has shown that the LINC02363 RNA is expressed at different levels in different samples, with higher levels in brain and muscle. The expression pattern of LINC02363 RNA may be influenced by the specific cell type or tissue, as well as the specific conditions used for the RNA extraction and purification.

Drug Targeting

LINC02363 RNA as a Drug Target

The unique structure and function of LINC02363 RNA make it an attractive candidate for drug targeting. The alternating sequence of non-coding regions and coding regions, as well as the high number of exons, suggests that LINC02363 RNA may be involved in the regulation of gene expression. Several studies have shown that LINC02363 RNA can interact with various proteins, including transcription factors, and that these interactions may play a role in the regulation of gene expression.

One potential mechanism by which LINC02363 RNA may be involved in drug targeting is by modulating the activity of transcription factors. Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences. LINC02363 RNA may interact with these transcription factors and alter their activity, which could have a profound impact on gene expression and ultimately lead to the regulation of cellular processes.

Biomarker Development

LINC02363 RNA as a Biomarker

LINC02363 RNA has also been identified as a potential biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. The unique structure and function of LINC02363 RNA make it an attractive candidate for diagnostic applications.

One potential mechanism by which LINC02363 RNA may be used as a biomarker is by its ability to interact with specific proteins that are involved in the development and progression of various diseases. For example, LINC02363 RNA has been shown to interact with

Protein Name: Long Intergenic Non-protein Coding RNA 2363

The "LINC02363 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02363 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets